pembrolizumab,durvalumab,toripalimab,nivolumab,ipilimumab
Merck,Astrazeneca,Coherus,Junshi Biosciences,bms
['congrat']
congratulations for this fantastic discussion (from a proud mentee). highlighting the need for clinical trial design to understand which patients need or not post operative adjuvant io to improve outcomes and avoid toxicities #asco23 
MD, PhD - Thoracic Oncologist. Precision Medicine Consultant & Co-Founder PxMedica and Medical Consultant @bradfordhill_cl.